1-7 of 7
Dahlia Sano
Close
Sort by
Journal Articles

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Manisha Lin, Jonathan Weiss, Tycel J. Phillips, Dahlia Sano, Shannon A. Carty, Monalisa Ghosh, Iman Ahmed, Victoria Nachar, David Hutton, Yasmin H. Karimi
Journal: Blood
Blood (2023) 142 (Supplement 1): 256.
https://doi.org/10.1182/blood-2023-182244
Published: 2023
Journal Articles

Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma

Dahlia Sano, Sairah Ahmed, Jingmin Liu, Scott Knowles, Seung Tae Lee
Journal: Blood
Blood (2022) 140 (Supplement 1): 12003–12004.
https://doi.org/10.1182/blood-2022-158225
Published: 2022
Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3560.
https://doi.org/10.1182/blood-2021-153683
Published: 2021
Journal Articles

Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Clinical Studies, and MD Anderson

Ethan Burns, MD, Kartik Anand, MD, Jason R. Westin, MD, Sai Ravi Kiran Pingali, MD, Joe Ensor, PhD, Dahlia Sano, MD, Loretta J. Nastoupil, MD MSc, Hun Ju Lee, Yago Nieto, MD PhD, Issa F. Khouri, MD, Felipe Samaniego, MD, Simrit Parmar, MBBS, Michael Wang, MD, Misha Hawkins, Sherry Adkins, ANP, Luis E. Fayad, MD, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, Sattva S Neelapu, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1931.
https://doi.org/10.1182/blood-2019-131077
Published: 2019
Journal Articles

Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse

Dahlia Sano, MD, Paolo Strati, MD, Pedro Alcedo, MD, V Ahalya Rao, MD, Prachee Singh, Roberto N. Miranda, MD, Jillian R Gunther, MD PhD, Chelsea Camille Pinnix, MD PhD, Bouthaina S. Dabaja, MD, Feng Lei, MS, Hun Ju Lee, MD, Raphael E Steiner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5291.
https://doi.org/10.1182/blood-2019-125980
Published: 2019
Journal Articles

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

Dahlia Sano, MBBCH, Loretta J. Nastoupil, MD, Nathan H. Fowler, MD, Luis Fayad, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Felipe Samaniego, MD, Michael Wang, MD, Maria Alma Rodriguez, MD, Swaminathan P Iyer, MD, Simrit Parmar, MBBS, Raphael Steiner, MD, Ranjit Nair, MBBS,MD, Sherry Adkins, ANP, Sara Arafat, MD, Ahalya Rao, MD, Liliana Vallejo, Misha Hawkins, Yiming Chen, Jason R. Westin, MD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 96.
https://doi.org/10.1182/blood-2018-99-120013
Published: 2018
Journal Articles

The Utility of End of Treatment PET-CT in Patients with Diffuse Large B-Cell Lymphoma and Documented Complete Remission By Interim PET

Dahlia Sano, MBBCH, Susan Szpunar, Kleanthe Kolizeras, Ayad Al-Katib, MD FACP
Journal: Blood
Blood (2017) 130 (Supplement 1): 4702.
https://doi.org/10.1182/blood.V130.Suppl_1.4702.4702
Published: 2017